Literature DB >> 23271792

AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling.

Kenneth M Fish1, Dennis Ladage, Yoshiaki Kawase, Ioannis Karakikes, Dongtak Jeong, Hung Ly, Kiyotake Ishikawa, Lahouaria Hadri, Lisa Tilemann, Jochen Muller-Ehmsen, R Jude Samulski, Evangelia G Kranias, Roger J Hajjar.   

Abstract

BACKGROUND: Heart failure is characterized by impaired function and disturbed Ca2+ homeostasis. Transgenic increases in inhibitor-1 activity have been shown to improve Ca2 cycling and preserve cardiac performance in the failing heart. The aim of this study was to evaluate the effect of activating the inhibitor (I-1c) of protein phosphatase 1 (I-1) through gene transfer on cardiac function in a porcine model of heart failure induced by myocardial infarction. METHODS AND
RESULTS: Myocardial infarction was created by a percutaneous, permanent left anterior descending artery occlusion in Yorkshire Landrace swine (n=16). One month after myocardial infarction, pigs underwent intracoronary delivery of either recombinant adeno-associated virus type 9 carrying I-1c (n=8) or saline (n=6) as control. One month after myocardial infarction was created, animals exhibited severe heart failure demonstrated by decreased ejection fraction (46.4±7.0% versus sham 69.7±8.5%) and impaired (dP/dt)max and (dP/dt)min. Intracoronary injection of AAV9.I-1c prevented further deterioration of cardiac function and led to a decrease in scar size.
CONCLUSIONS: In this preclinical model of heart failure, overexpression of I-1c by intracoronary in vivo gene transfer preserved cardiac function and reduced the scar size.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271792      PMCID: PMC3605211          DOI: 10.1161/CIRCHEARTFAILURE.112.971325

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  29 in total

1.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1.

Authors:  Anand Pathak; Federica del Monte; Wen Zhao; Jo-El Schultz; John N Lorenz; Ilona Bodi; Doug Weiser; Harvey Hahn; Andrew N Carr; Faisal Syed; Nirmala Mavila; Leena Jha; Jiang Qian; Yehia Marreez; Guoli Chen; Dennis W McGraw; E Kevin Heist; J Luis Guerrero; Anna A DePaoli-Roach; Roger J Hajjar; Evangelia G Kranias
Journal:  Circ Res       Date:  2005-03-03       Impact factor: 17.367

3.  Increased expression of cardiac phosphatases in patients with end-stage heart failure.

Authors:  J Neumann; T Eschenhagen; L R Jones; B Linck; W Schmitz; H Scholz; N Zimmermann
Journal:  J Mol Cell Cardiol       Date:  1997-01       Impact factor: 5.000

4.  Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function.

Authors:  Patricia Rodriguez; Bryan Mitton; Jason R Waggoner; Evangelia G Kranias
Journal:  J Biol Chem       Date:  2006-10-17       Impact factor: 5.157

5.  Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy.

Authors:  Ali El-Armouche; Katrin Wittköpper; Franziska Degenhardt; Florian Weinberger; Michael Didié; Ivan Melnychenko; Michael Grimm; Micha Peeck; Wolfram H Zimmermann; Bernhard Unsöld; Gerd Hasenfuss; Dobromir Dobrev; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2008-08-08       Impact factor: 10.787

6.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712

7.  Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.

Authors:  Roger J Hajjar; Krisztina Zsebo; Lawrence Deckelbaum; Craig Thompson; Jeff Rudy; Alex Yaroshinsky; Hung Ly; Yoshiaki Kawase; Kim Wagner; Kenneth Borow; Brian Jaski; Barry London; Barry Greenberg; Daniel F Pauly; Richard Patten; Randall Starling; Donna Mancini; Mariell Jessup
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

8.  A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation.

Authors:  Guoli Chen; Xiaoyang Zhou; Persoulla Nicolaou; Patricia Rodriguez; Guojie Song; Bryan Mitton; Anand Pathak; Amit Zachariah; Guo-Chang Fan; Gerald W Dorn; Evangelia G Kranias
Journal:  FASEB J       Date:  2008-01-11       Impact factor: 5.191

9.  Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes.

Authors:  Patricia Rodriguez; Bryan Mitton; Persoulla Nicolaou; Guoli Chen; Evangelia G Kranias
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-06       Impact factor: 4.733

10.  Prevalence of anatomical variants and coronary anomalies in 543 consecutive patients studied with 64-slice CT coronary angiography.

Authors:  Filippo Cademartiri; Ludovico La Grutta; Roberto Malagò; Filippo Alberghina; Willem B Meijboom; Francesca Pugliese; Erica Maffei; Anselmo Alessandro Palumbo; Annachiara Aldrovandi; Michele Fusaro; Valerio Brambilla; Paolo Coruzzi; Massimo Midiri; Nico R A Mollet; Gabriel P Krestin
Journal:  Eur Radiol       Date:  2008-02-02       Impact factor: 5.315

View more
  32 in total

Review 1.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue.

Authors:  Dan Wang; Li Zhong; M Abu Nahid; Guangping Gao
Journal:  Expert Opin Drug Deliv       Date:  2014-01-03       Impact factor: 6.648

2.  Up-regulation of micro-RNA765 in human failing hearts is associated with post-transcriptional regulation of protein phosphatase inhibitor-1 and depressed contractility.

Authors:  Wen-Feng Cai; Guan-Sheng Liu; Chi Keung Lam; Stela Florea; Jiang Qian; Wen Zhao; Tracy Pritchard; Kobra Haghighi; Djamel Lebeche; Long Jason Lu; Jingyuan Deng; Guo-Chang Fan; Roger J Hajjar; Evangelia G Kranias
Journal:  Eur J Heart Fail       Date:  2015-07-15       Impact factor: 15.534

3.  Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure.

Authors:  Kiyotake Ishikawa; Kenneth M Fish; Lisa Tilemann; Kleopatra Rapti; Jaume Aguero; Carlos G Santos-Gallego; Ahyoung Lee; Ioannis Karakikes; Chaoqin Xie; Fadi G Akar; Yuichi J Shimada; Judith K Gwathmey; Aravind Asokan; Scott McPhee; Jade Samulski; Richard Jude Samulski; Daniel C Sigg; Thomas Weber; Evangelia G Kranias; Roger J Hajjar
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

4.  Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure.

Authors:  Shin Watanabe; Kiyotake Ishikawa; Kenneth Fish; Jae Gyun Oh; Lukas J Motloch; Erik Kohlbrenner; Philyoung Lee; Chaoqin Xie; Ahyoung Lee; Lifan Liang; Changwon Kho; Lauren Leonardson; Maritza McIntyre; Scott Wilson; R Jude Samulski; Evangelia G Kranias; Thomas Weber; Fadi G Akar; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2017-10-03       Impact factor: 24.094

Review 5.  Serine/Threonine Phosphatases in Atrial Fibrillation.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Xander H T Wehrens; Dobromir Dobrev
Journal:  J Mol Cell Cardiol       Date:  2017-01-07       Impact factor: 5.000

Review 6.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

7.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

Review 8.  Adeno-associated virus-mediated gene therapy in cardiovascular disease.

Authors:  Nadjib Hammoudi; Kiyotake Ishikawa; Roger J Hajjar
Journal:  Curr Opin Cardiol       Date:  2015-05       Impact factor: 2.161

Review 9.  Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure.

Authors:  Michael G Katz; Anthony S Fargnoli; Thomas Weber; Roger J Hajjar; Charles R Bridges
Journal:  Hum Gene Ther Clin Dev       Date:  2017-07-19       Impact factor: 5.032

Review 10.  Human Cardiac Gene Therapy.

Authors:  Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.